Merck & Co., Inc. MRK Financial Statement Data


2025 Q2

Submissions

Field Row 1
adsh 0001628280-25-021834
cik 310158
name MERCK & CO., INC.
sic 2834
countryba US
stprba NJ
cityba RAHWAY
zipba 07065
bas1 126 EAST LINCOLN AVENUE
bas2 P.O. BOX 2000
baph 908-740-4000
countryma US
stprma NJ
cityma RAHWAY
zipma 07065
mas1 126 EAST LINCOLN AVENUE
mas2 P.O. BOX 2000
countryinc US
stprinc NJ
ein 221918501
former MERCK & CO. INC.
changed 20091103
afs 1-LAF
wksi 0
fye 1231
form 10-Q
period 20250331
fy 2025
fp Q1
filed 20250502
accepted 2025-05-02 16:10:00.0
prevrpt 0
detail 1
instance mrk-20250331_htm.xml
nciks 1
aciks

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
cik Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings.
name Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date.
sic Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business.
countryba The ISO 3166-1 country of the registrant's business address.
stprba The state or province of the registrant’s business address, if field countryba is US or CA.
cityba The city of the registrant's business address.
zipba The zip code of the registrant’s business address.
bas1 The first line of the street of the registrant’s business address.
bas2 The second line of the street of the registrant’s business address.
baph The phone number of the registrant’s business address.
countryma The ISO 3166-1 country of the registrant's mailing address.
stprma The state or province of the registrant’s mailing address, if field countryma is US or CA.
cityma The city of the registrant's mailing address.
zipma The zip code of the registrant’s mailing address.
mas1 The first line of the street of the registrant’s mailing address.
mas2 The second line of the street of the registrant’s mailing address.
countryinc The ISO 3166-1 country of incorporation for the registrant.
stprinc The state or province of incorporation for the registrant, if countryinc is US or CA.
ein Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States.
former Most recent former name of the registrant, if any.
changed Date of change from the former name, if any.
afs Filer status with the SEC at the time of submission:
1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned.
wksi Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement.
fye Fiscal Year End Date, rounded to nearest month-end.
form The submission type of the registrant’s filing.
period Balance Sheet Date, rounded to nearest month-end.
fy Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8).
fp Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year.
filed The date of the registrant’s filing with the Commission.
accepted The acceptance date and time of the registrant’s filing with the Commission.
prevrpt Previous Report – TRUE indicates that the submission information was subsequently amended.
detail TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount).
instance The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol.
nciks Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing.
aciks Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information.

Numbers

adsh ddate tag value uom qtrs version segments coreg footnote
0001628280-25-021834 20250331 Accounts Payable Current 3784000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20241231 Accrued Income Taxes Current 3914000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20241231 Additional Paid In Capital Common Stock 44704000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20240331 Adjustment For Amortization 473000000.0000 USD 1 us-gaap/2024 Consolidation Items= Corporate Non Segment;
0001628280-25-021834 20250331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 8732000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20250331 Cost Of Goods And Services Sold 3419000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20250331 Cost Of Goods And Services Sold 53000000.0000 USD 1 us-gaap/2024 Counterparty Name= Ridgeback Biotherapeutics L P; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20250331 Debt Current 1360000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20250331 Equity Securities Fv Ni Gain Loss -23000000.0000 USD 1 us-gaap/2024 Financial Instrument= Equity Funds;
0001628280-25-021834 20240331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest 5670000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20250331 Net Income Loss 5079000000.0000 USD 1 us-gaap/2024 Equity Components= Retained Earnings;
0001628280-25-021834 20241231 Other Assets Noncurrent 0.0000 USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level2; Fair Value By Measurement Frequency= Fair Value Measurements Recurring;
0001628280-25-021834 20241231 Other Liabilities Current 15694000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20241231 Other Liabilities Current 82000000.0000 USD 0 us-gaap/2024 Counterparty Name= Bayer A G; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20250331 Other Liabilities Current 12772000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20250331 Other Liabilities Current 803000000.0000 USD 0 us-gaap/2024 Counterparty Name= Daiichi Sankyo; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20250331 Other Liabilities Current 43000000.0000 USD 0 us-gaap/2024 Counterparty Name= Ridgeback Biotherapeutics L P; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20250331 Other Nonoperating Income Expense -1000000.0000 USD 1 us-gaap/2024 Business Segments= Animal Healthsegment; Consolidation Items= Operating Segments;
0001628280-25-021834 20250331 Payments For Proceeds From Other Investing Activities 20000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20240331 Proceeds From Payments For Other Financing Activities -78000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20250331 Proceeds From Payments For Other Financing Activities -60000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20240331 Profit Loss 4767000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20241231 Property Plant And Equipment Net 202000000.0000 USD 0 us-gaap/2024 Geographical= C N;
0001628280-25-021834 20241231 Property Plant And Equipment Net 47000000.0000 USD 0 us-gaap/2024 Geographical= Other Countries;
0001628280-25-021834 20241231 Property Plant And Equipment Net 14724000000.0000 USD 0 us-gaap/2024 Geographical= U S;
0001628280-25-021834 20250331 Property Plant And Equipment Net 24793000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20250331 Property Plant And Equipment Net 973000000.0000 USD 0 us-gaap/2024 Geographical= Asia Pacific;
0001628280-25-021834 20250331 Property Plant And Equipment Net 198000000.0000 USD 0 us-gaap/2024 Geographical= C N;
0001628280-25-021834 20240331 Research And Development Expense 3851000000.0000 USD 1 us-gaap/2024 Consolidation Items= Corporate Non Segment;
0001628280-25-021834 20231231 Restricted Cash And Cash Equivalents 68000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20250331 Restructuring Charges 69000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20250331 Retained Earnings Accumulated Deficit 66097000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20240331 Revenues 1511000000.0000 USD 1 us-gaap/2024 Business Segments= Animal Healthsegment; Consolidation Items= Operating Segments;
0001628280-25-021834 20240331 Revenues 354000000.0000 USD 1 us-gaap/2024 Business Segments= Animal Healthsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Companion Animal;
0001628280-25-021834 20240331 Revenues 14006000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments;
0001628280-25-021834 20240331 Revenues 12000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Alliance Revenue Reblozyl;
0001628280-25-021834 20240331 Revenues 212000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Janumet;
0001628280-25-021834 20240331 Revenues 467000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Other Pharmaceutical;
0001628280-25-021834 20240331 Revenues 55000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Pneumovax23;
0001628280-25-021834 20240331 Revenues 58000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Vaxneuvance;
0001628280-25-021834 20240331 Revenues 6936000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S;
0001628280-25-021834 20240331 Revenues 0.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Simponi;
0001628280-25-021834 20240331 Revenues 33000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Zerbaxa;
0001628280-25-021834 20240331 Revenues 0.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Capvaxive;
0001628280-25-021834 20240331 Revenues 2249000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Gardasil Gardasil9;
0001628280-25-021834 20240331 Revenues 111000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Isentress Isentress H D;
0001628280-25-021834 20240331 Revenues 70000000.0000 USD 1 us-gaap/2024 Counterparty Name= Bayer A G; Product Or Service= Adempas; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20240331 Revenues 44000000.0000 USD 1 us-gaap/2024 Derivative Instrument Risk= Foreign Exchange Contract; Equity Components= Accumulated Gain Loss Cash Flow Hedge Including Noncontrolling Interest; Reclassification Out Of Accumulated Other Comprehensive Income= Reclassification Out Of Accumulated Other Comprehensive Income;
0001628280-25-021834 20250331 Revenues 182000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Janumet;
0001628280-25-021834 20250331 Revenues 2897000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Keytruda;
0001628280-25-021834 20250331 Revenues 67000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Lagevrio;
0001628280-25-021834 20250331 Revenues 72000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Lenvima;
0001628280-25-021834 20250331 Revenues 545000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Other Pharmaceutical;
0001628280-25-021834 20250331 Revenues 13000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Pifeltro;
0001628280-25-021834 20250331 Revenues 106000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Prevymis;
0001628280-25-021834 20250331 Revenues 101000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Alliance Revenue Reblozyl;
0001628280-25-021834 20250331 Revenues 51000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Isentress Isentress H D;
0001628280-25-021834 20250331 Revenues 208000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Prevymis;
0001628280-25-021834 20250331 Revenues 228000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Rotateq;
0001628280-25-021834 20240331 Selling General And Administrative Expense 2483000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20240331 Selling General And Administrative Expense 39000000.0000 USD 1 us-gaap/2024 Counterparty Name= Astra Zeneca; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20250331 Selling General And Administrative Expense 6000000.0000 USD 1 us-gaap/2024 Counterparty Name= Moderna Inc.; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 40424000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20241231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -2327000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Defined Benefit Plans Adjustment;
0001628280-25-021834 20241231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -4945000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001628280-25-021834 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -4965000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001628280-25-021834 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 65000000.0000 USD 0 us-gaap/2024 Equity Components= Noncontrolling Interest;
0001628280-25-021834 20231231 Treasury Stock Common Shares 1045000000.0000 shares 0 us-gaap/2024 Equity Components= Treasury Stock Common;
0001628280-25-021834 20250331 Treasury Stock Common Shares 1061021894.0000 shares 0 us-gaap/2024
0001628280-25-021834 20240331 Cost Of Goods And Services Sold 3540000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20250331 Accumulated Depreciation Depletion And Amortization Property Plant And Equipment 19680000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20241231 Accumulated Other Comprehensive Income Loss Net Of Tax -4945000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20250331 Adjustment For Amortization 597000000.0000 USD 1 us-gaap/2024 Consolidation Items= Corporate Non Segment;
0001628280-25-021834 20241231 Allowance For Doubtful Accounts Receivable Current 89000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20241231 Assets 117106000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20241231 Common Stock Shares Issued 3577000000.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0001628280-25-021834 20250331 Cost Of Goods And Services Sold 1573000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments;
0001628280-25-021834 20250331 Depreciation 60000000.0000 USD 1 us-gaap/2024 Business Segments= Animal Healthsegment; Consolidation Items= Operating Segments;
0001628280-25-021834 20240331 Earnings Per Share Basic 1.8800 USD 1 us-gaap/2024
0001628280-25-021834 20250331 Earnings Per Share Diluted 2.0100 USD 1 us-gaap/2024
0001628280-25-021834 20250331 Inventory Noncurrent 4000000000.0000 USD 0 us-gaap/2024 Public Utilities Inventory= Inventory Not Expectedtobe Sold Within One Year;
0001628280-25-021834 20250331 Net Cash Provided By Used In Investing Activities -1487000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20250331 Net Income Loss 5079000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20240331 Net Income Loss Attributable To Noncontrolling Interest 5000000.0000 USD 1 us-gaap/2024 Equity Components= Noncontrolling Interest;
0001628280-25-021834 20250331 Other Assets Noncurrent 508000000.0000 USD 0 us-gaap/2024 Fair Value By Measurement Frequency= Fair Value Measurements Recurring;
0001628280-25-021834 20241231 Other Liabilities Current 713000000.0000 USD 0 us-gaap/2024 Counterparty Name= Astra Zeneca; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20250331 Other Liabilities Current 15000000.0000 USD 0 us-gaap/2024 Counterparty Name= Astra Zeneca; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20241231 Common Stock Shares Issued 3577103522.0000 shares 0 us-gaap/2024
0001628280-25-021834 20250331 Assets 115122000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20241231 Assets Current 257000000.0000 USD 0 us-gaap/2024 Counterparty Name= Eisai; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20250331 Assets Current 35503000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20250331 Assets Current 358000000.0000 USD 0 us-gaap/2024 Counterparty Name= Astra Zeneca; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20241231 Other Liabilities Noncurrent 6465000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20250331 Other Noncash Income Expense -109000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20240331 Other Nonoperating Income Expense 33000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20240331 Other Nonoperating Income Expense -33000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments;
0001628280-25-021834 20250331 Other Nonoperating Income Expense -49000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments;
0001628280-25-021834 20240331 Payments To Acquire Businesses Net Of Cash Acquired 746000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20250331 Payments To Acquire Businesses Net Of Cash Acquired 0.0000 USD 1 us-gaap/2024
0001628280-25-021834 20250331 Property Plant And Equipment Net 14891000000.0000 USD 0 us-gaap/2024 Geographical= U S;
0001628280-25-021834 20250331 Research And Development Asset Acquired Other Than Through Business Combination Written Off 0.0000 USD 1 us-gaap/2024
0001628280-25-021834 20240331 Research And Development Expense 90000000.0000 USD 1 us-gaap/2024 Business Segments= Animal Healthsegment; Consolidation Items= Operating Segments;
0001628280-25-021834 20250331 Restructuring Charges 69000000.0000 USD 1 us-gaap/2024 Consolidation Items= Corporate Non Segment;
0001628280-25-021834 20240331 Revenues 1037000000.0000 USD 1 us-gaap/2024 Business Segments= Animal Healthsegment; Consolidation Items= Operating Segments; Geographical= Non Us;
0001628280-25-021834 20240331 Revenues 683000000.0000 USD 1 us-gaap/2024 Business Segments= Animal Healthsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Livestock;
0001628280-25-021834 20240331 Revenues 61000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Isentress Isentress H D;
0001628280-25-021834 20240331 Revenues 305000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Lagevrio;
0001628280-25-021834 20240331 Revenues 58000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Alliance Revenue Reblozyl;
0001628280-25-021834 20240331 Revenues 438000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Pro Quad M M R I I Varivax;
0001628280-25-021834 20240331 Revenues 6947000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Keytruda;
0001628280-25-021834 20240331 Revenues 42000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Pifeltro;
0001628280-25-021834 20240331 Revenues 174000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Prevymis;
0001628280-25-021834 20240331 Revenues 216000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Rotateq;
0001628280-25-021834 20240331 Revenues 5000000.0000 USD 1 us-gaap/2024 Counterparty Name= Bayer A G; Product Or Service= Verquvo; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20240331 Revenues 724000000.0000 USD 1 us-gaap/2024 Geographical= Asia Pacific;
0001628280-25-021834 20240331 Revenues 821000000.0000 USD 1 us-gaap/2024 Geographical= J P;
0001628280-25-021834 20240331 Revenues 621000000.0000 USD 1 us-gaap/2024 Geographical= Other Countries;
0001628280-25-021834 20250331 Revenues 15529000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20250331 Revenues 68000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Adempas;
0001628280-25-021834 20250331 Revenues 790000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Gardasil Gardasil9;
0001628280-25-021834 20250331 Revenues 12000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Winrevair;
0001628280-25-021834 20250331 Revenues 145000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Alliancerevenue Lynparza;
0001628280-25-021834 20250331 Revenues 65000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Janumet;
0001628280-25-021834 20250331 Revenues 35000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Lagevrio;
0001628280-25-021834 20250331 Revenues 184000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Other Pharmaceutical;
0001628280-25-021834 20250331 Revenues 123000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Welireg;
0001628280-25-021834 20250331 Revenues 107000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Capvaxive;
0001628280-25-021834 20250331 Revenues 41000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Pneumovax23;
0001628280-25-021834 20250331 Revenues 6797000000.0000 USD 1 us-gaap/2024 Consolidation Items= Operating Segments; Geographical= Non Us;
0001628280-25-021834 20250331 Revenues 183000000.0000 USD 1 us-gaap/2024 Counterparty Name= Bayer A G; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20250331 Revenues 3454000000.0000 USD 1 us-gaap/2024 Geographical= E M E A;
0001628280-25-021834 20240331 Selling General And Administrative Expense 1429000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments;
0001628280-25-021834 20250331 Selling General And Administrative Expense 2552000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20241231 Stockholders Equity 46313000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20231231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -24000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Gain Loss Net Cash Flow Hedge Parent;
0001628280-25-021834 20231231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -2344000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Translation Adjustment;
0001628280-25-021834 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 60000000.0000 USD 0 us-gaap/2024 Equity Components= Noncontrolling Interest;
0001628280-25-021834 20241231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 242000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Gain Loss Net Cash Flow Hedge Parent;
0001628280-25-021834 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -2645000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Translation Adjustment;
0001628280-25-021834 20241231 Common Stock Shares Authorized 6500000000.0000 shares 0 us-gaap/2024
0001628280-25-021834 20250331 Assets Current 263000000.0000 USD 0 us-gaap/2024 Counterparty Name= Eisai; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20240331 Cost Of Goods And Services Sold 613000000.0000 USD 1 us-gaap/2024 Business Segments= Animal Healthsegment; Consolidation Items= Operating Segments;
0001628280-25-021834 20240331 Cost Of Goods And Services Sold 82000000.0000 USD 1 us-gaap/2024 Counterparty Name= Astra Zeneca; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20240331 Cost Of Goods And Services Sold 191000000.0000 USD 1 us-gaap/2024 Counterparty Name= Ridgeback Biotherapeutics L P; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20250331 Cost Of Goods And Services Sold 60000000.0000 USD 1 us-gaap/2024 Counterparty Name= Eisai; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20240331 Depreciation 59000000.0000 USD 1 us-gaap/2024 Consolidation Items= Operating Segments;
0001628280-25-021834 20240331 Equity Securities Fv Ni Gain Loss 143000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20240331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest 555000000.0000 USD 1 us-gaap/2024 Business Segments= Animal Healthsegment; Consolidation Items= Operating Segments;
0001628280-25-021834 20250331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest 5903000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20250331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest 202000000.0000 USD 1 us-gaap/2024 Consolidation Items= Corporate Non Segment;
0001628280-25-021834 20240331 Increase Decrease In Operating Capital 3382000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20250331 Inventory Net 6196000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20241231 Liabilities Current 28420000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20241231 Other Assets Current 8000000.0000 USD 0 us-gaap/2024 Counterparty Name= Daiichi Sankyo; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20250331 Other Assets Current 9289000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20240331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent -113000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20241231 Other Liabilities Current 817000000.0000 USD 0 us-gaap/2024 Counterparty Name= Daiichi Sankyo; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20240331 Other Noncash Income Expense -83000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20240331 Payments For Repurchase Of Common Stock 122000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20250331 Payments For Repurchase Of Common Stock 1164000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20250331 Payments To Acquire Investments 595000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20250331 Payments To Acquire Property Plant And Equipment 1328000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20241231 Property Plant And Equipment Net 133000000.0000 USD 0 us-gaap/2024 Geographical= Latin America;
0001628280-25-021834 20250331 Property Plant And Equipment Net 135000000.0000 USD 0 us-gaap/2024 Geographical= Latin America;
0001628280-25-021834 20240331 Research And Development Expense 3992000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20240331 Research And Development Expense 656000000.0000 USD 1 us-gaap/2024 Asset Acquisition= Harpoon Therapeutics Inc.;
0001628280-25-021834 20240331 Research And Development Expense 0.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments;
0001628280-25-021834 20250331 Research And Development Expense 0.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments;
0001628280-25-021834 20250331 Research And Development Expense 3477000000.0000 USD 1 us-gaap/2024 Consolidation Items= Corporate Non Segment;
0001628280-25-021834 20250331 Research And Development Expense 86000000.0000 USD 1 us-gaap/2024 Counterparty Name= Moderna Inc.; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20241231 Restricted Cash And Cash Equivalents 76000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20250331 Restricted Cash And Cash Equivalents 103000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20240331 Restructuring Charges 123000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20240331 Revenues 661000000.0000 USD 1 us-gaap/2024 Business Segments= Animal Healthsegment; Consolidation Items= Operating Segments; Product Or Service= Companion Animal;
0001628280-25-021834 20240331 Revenues 111000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Bridion;
0001628280-25-021834 20240331 Revenues 5000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Dificid;
0001628280-25-021834 20240331 Revenues 39000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Janumet;
0001628280-25-021834 20240331 Revenues 77000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Welireg;
0001628280-25-021834 20240331 Revenues 292000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Alliancerevenue Lynparza;
0001628280-25-021834 20240331 Revenues 350000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Lagevrio;
0001628280-25-021834 20240331 Revenues 61000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Pneumovax23;
0001628280-25-021834 20240331 Revenues 570000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Pro Quad M M R I I Varivax;
0001628280-25-021834 20240331 Revenues 39000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Remicade;
0001628280-25-021834 20240331 Revenues 85000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Welireg;
0001628280-25-021834 20240331 Revenues 190000000.0000 USD 1 us-gaap/2024 Consolidation Items= Corporate Non Segment; Geographical= Non Us;
0001628280-25-021834 20240331 Revenues 7410000000.0000 USD 1 us-gaap/2024 Consolidation Items= Operating Segments; Geographical= U S;
0001628280-25-021834 20240331 Revenues 350000000.0000 USD 1 us-gaap/2024 Counterparty Name= Ridgeback Biotherapeutics L P; Product Or Service= Lagevrio; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20240331 Revenues 1772000000.0000 USD 1 us-gaap/2024 Geographical= C N;
0001628280-25-021834 20250331 Revenues 13638000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments;
0001628280-25-021834 20250331 Revenues 63000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Bridion;
0001628280-25-021834 20250331 Revenues 11000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Dificid;
0001628280-25-021834 20250331 Revenues 7927000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S;
0001628280-25-021834 20250331 Revenues 378000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Bridion;
0001628280-25-021834 20250331 Revenues 344000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Januvia;
0001628280-25-021834 20250331 Revenues 42000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Zerbaxa;
0001628280-25-021834 20250331 Revenues 119000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Alliance Revenue Reblozyl;
0001628280-25-021834 20250331 Revenues 50000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Belsomra;
0001628280-25-021834 20250331 Revenues 441000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Bridion;
0001628280-25-021834 20250331 Revenues 83000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Dificid;
0001628280-25-021834 20250331 Revenues 90000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Isentress Isentress H D;
0001628280-25-021834 20250331 Revenues 729000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Other Pharmaceutical;
0001628280-25-021834 20250331 Revenues 230000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Vaxneuvance;
0001628280-25-021834 20250331 Revenues 303000000.0000 USD 1 us-gaap/2024 Consolidation Items= Corporate Non Segment;
0001628280-25-021834 20250331 Revenues 15226000000.0000 USD 1 us-gaap/2024 Consolidation Items= Operating Segments;
0001628280-25-021834 20240331 Selling General And Administrative Expense 2000000.0000 USD 1 us-gaap/2024 Counterparty Name= Moderna Inc.; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20250331 Selling General And Administrative Expense 32000000.0000 USD 1 us-gaap/2024 Counterparty Name= Astra Zeneca; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20250331 Selling General And Administrative Expense 13000000.0000 USD 1 us-gaap/2024 Counterparty Name= Ridgeback Biotherapeutics L P; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20250331 Stockholders Equity 48335000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20241231 Stockholders Equity Before Treasury Stock 104616000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20250331 Stockholders Equity Before Treasury Stock 107736000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20231231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 37635000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20231231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 1788000000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001628280-25-021834 20231231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 54000000.0000 USD 0 us-gaap/2024 Equity Components= Noncontrolling Interest;
0001628280-25-021834 20231231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -57450000000.0000 USD 0 us-gaap/2024 Equity Components= Treasury Stock Common;
0001628280-25-021834 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -2798000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Defined Benefit Plans Adjustment;
0001628280-25-021834 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -2582000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Translation Adjustment;
0001628280-25-021834 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 44598000000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001628280-25-021834 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 1788000000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001628280-25-021834 20241231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -58303000000.0000 USD 0 us-gaap/2024 Equity Components= Treasury Stock Common;
0001628280-25-021834 20241231 Treasury Stock Common Shares 1049466187.0000 shares 0 us-gaap/2024
0001628280-25-021834 20241231 Treasury Stock Common Value 58303000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20250331 Adjustment For Amortization 597000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20241231 Assets Current 38782000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20241231 Assets Current 424000000.0000 USD 0 us-gaap/2024 Counterparty Name= Astra Zeneca; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20250331 Common Stock Shares Authorized 6500000000.0000 shares 0 us-gaap/2024
0001628280-25-021834 20240331 Common Stock Shares Issued 3577000000.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0001628280-25-021834 20250331 Cost Of Goods And Services Sold 600000000.0000 USD 1 us-gaap/2024 Business Segments= Animal Healthsegment; Consolidation Items= Operating Segments;
0001628280-25-021834 20250331 Deferred Income Tax Expense Benefit -186000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20240331 Income Tax Expense Benefit 903000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20250331 Increase Decrease In Operating Capital 3712000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20241231 Intangible Assets Net Excluding Goodwill 16370000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20241231 Inventory Noncurrent 3800000000.0000 USD 0 us-gaap/2024 Public Utilities Inventory= Inventory Not Expectedtobe Sold Within One Year;
0001628280-25-021834 20241231 Liabilities And Stockholders Equity 117106000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20241231 Long Term Debt Noncurrent 34462000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20240331 Net Cash Provided By Used In Operating Activities 3090000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20240331 Net Income Loss Attributable To Noncontrolling Interest 5000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20250331 Net Income Loss Attributable To Noncontrolling Interest 6000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20241231 Other Assets Noncurrent 0.0000 USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level3; Fair Value By Measurement Frequency= Fair Value Measurements Recurring;
0001628280-25-021834 20250331 Other Assets Noncurrent 508000000.0000 USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level1; Fair Value By Measurement Frequency= Fair Value Measurements Recurring;
0001628280-25-021834 20250331 Other Assets Noncurrent 0.0000 USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level2; Fair Value By Measurement Frequency= Fair Value Measurements Recurring;
0001628280-25-021834 20240331 Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent 5000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20250331 Other Liabilities Noncurrent 6655000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20250331 Other Nonoperating Income Expense 35000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20240331 Payments To Acquire Investments 15000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20240331 Proceeds From Stock Options Exercised 87000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20250331 Profit Loss 5085000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20240331 Research And Development Asset Acquired Other Than Through Business Combination Written Off 656000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20240331 Research And Development Expense 8000000.0000 USD 1 us-gaap/2024 Counterparty Name= Eisai; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20250331 Research And Development Expense 12000000.0000 USD 1 us-gaap/2024 Counterparty Name= Astra Zeneca; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20250331 Research And Development Expense 5000000.0000 USD 1 us-gaap/2024 Counterparty Name= Eisai; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20240331 Revenues 2828000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Keytruda;
0001628280-25-021834 20240331 Revenues 100000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Prevymis;
0001628280-25-021834 20240331 Revenues 184000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Simponi;
0001628280-25-021834 20240331 Revenues 0.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Winrevair;
0001628280-25-021834 20240331 Revenues 12000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Delstrigo;
0001628280-25-021834 20240331 Revenues 488000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Gardasil Gardasil9;
0001628280-25-021834 20240331 Revenues 0.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Remicade;
0001628280-25-021834 20240331 Revenues 98000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Alliance Revenue Adempas Verquvo;
0001628280-25-021834 20240331 Revenues 71000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Alliance Revenue Reblozyl;
0001628280-25-021834 20240331 Revenues 255000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Lenvima;
0001628280-25-021834 20240331 Revenues 68000000.0000 USD 1 us-gaap/2024 Consolidation Items= Corporate Non Segment; Geographical= U S;
0001628280-25-021834 20250331 Revenues 730000000.0000 USD 1 us-gaap/2024 Business Segments= Animal Healthsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Livestock;
0001628280-25-021834 20250331 Revenues 308000000.0000 USD 1 us-gaap/2024 Business Segments= Animal Healthsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Companion Animal;
0001628280-25-021834 20250331 Revenues 194000000.0000 USD 1 us-gaap/2024 Business Segments= Animal Healthsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Livestock;
0001628280-25-021834 20250331 Revenues 9000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Alliance Revenue Adempas Verquvo;
0001628280-25-021834 20250331 Revenues 52000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Delstrigo;
0001628280-25-021834 20250331 Revenues 0.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Remicade;
0001628280-25-021834 20250331 Revenues 536000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Gardasil Gardasil9;
0001628280-25-021834 20250331 Revenues 32000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Pifeltro;
0001628280-25-021834 20250331 Revenues 139000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Vaxneuvance;
0001628280-25-021834 20250331 Revenues 68000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Adempas;
0001628280-25-021834 20250331 Revenues 312000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Alliancerevenue Lynparza;
0001628280-25-021834 20250331 Revenues 539000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Pro Quad M M R I I Varivax;
0001628280-25-021834 20250331 Revenues 280000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Winrevair;
0001628280-25-021834 20250331 Revenues 70000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Zerbaxa;
0001628280-25-021834 20250331 Revenues 102000000.0000 USD 1 us-gaap/2024 Counterparty Name= Ridgeback Biotherapeutics L P; Product Or Service= Lagevrio; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20250331 Selling General And Administrative Expense 31000000.0000 USD 1 us-gaap/2024 Counterparty Name= Eisai; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20240331 Share Based Compensation 176000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20231231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -5161000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001628280-25-021834 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 25000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Gain Loss Net Cash Flow Hedge Parent;
0001628280-25-021834 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 44816000000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001628280-25-021834 20241231 Treasury Stock Common Shares 1049000000.0000 shares 0 us-gaap/2024 Equity Components= Treasury Stock Common;
0001628280-25-021834 20250331 Accounts Receivable Net Current 10790000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20241231 Assets Current 160000000.0000 USD 0 us-gaap/2024 Counterparty Name= Bayer A G; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20240331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect -1238000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20241231 Common Stock Value 1788000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20250331 Depreciation 502000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20250331 Depreciation 1000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments;
0001628280-25-021834 20250331 Depreciation 61000000.0000 USD 1 us-gaap/2024 Consolidation Items= Operating Segments;
0001628280-25-021834 20250331 Dividends Payable Current 2077000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20250331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest 10712000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments;
0001628280-25-021834 20250331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest 11346000000.0000 USD 1 us-gaap/2024 Consolidation Items= Operating Segments;
0001628280-25-021834 20241231 Inventory Noncurrent 412000000.0000 USD 0 us-gaap/2024 Public Utilities Inventory= Inventories Producedin Preparationfor Product Launches;
0001628280-25-021834 20250331 Inventory Noncurrent 4556000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20250331 Liabilities And Stockholders Equity 115122000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20250331 Liabilities Current 25174000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20241231 Minority Interest 59000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20250331 Net Cash Provided By Used In Operating Activities 2500000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20240331 Net Income Loss 4762000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20241231 Other Assets Current 8706000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20240331 Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent 130000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20250331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent -20000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20250331 Other Liabilities Current 37000000.0000 USD 0 us-gaap/2024 Counterparty Name= Moderna Inc.; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20240331 Payments Of Dividends Common Stock 1950000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20250331 Proceeds From Sale And Maturity Of Other Investments 456000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20250331 Property Plant And Equipment Net 759000000.0000 USD 0 us-gaap/2024 Asset Acquisition= Wu Xi Vaccines Facility; Property Plant And Equipment By Type= Asset Under Construction;
0001628280-25-021834 20240331 Research And Development Expense 28000000.0000 USD 1 us-gaap/2024 Counterparty Name= Bayer A G; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20240331 Research And Development Expense 69000000.0000 USD 1 us-gaap/2024 Counterparty Name= Daiichi Sankyo; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20240331 Research And Development Expense 69000000.0000 USD 1 us-gaap/2024 Counterparty Name= Moderna Inc.; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20241231 Accounts Payable Current 4079000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20241231 Accounts Receivable Net Current 10278000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20250331 Accrued Income Taxes Current 5181000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20250331 Accumulated Other Comprehensive Income Loss Net Of Tax -4965000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20250331 Additional Paid In Capital Common Stock 44816000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20250331 Research And Development Expense 24000000.0000 USD 1 us-gaap/2024 Counterparty Name= Bayer A G; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20250630 Research And Development Expense 200000000.0000 USD 1 us-gaap/2024 Asset Acquisition= H R S5346 Jiangsu Hengrui Pharmaceuticals Co. Ltd.; Scenario= Scenario Forecast;
0001628280-25-021834 20240331 Revenues 15775000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20240331 Revenues 166000000.0000 USD 1 us-gaap/2024 Business Segments= Animal Healthsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Livestock;
0001628280-25-021834 20240331 Revenues 850000000.0000 USD 1 us-gaap/2024 Business Segments= Animal Healthsegment; Consolidation Items= Operating Segments; Product Or Service= Livestock;
0001628280-25-021834 20240331 Revenues 329000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Bridion;
0001628280-25-021834 20240331 Revenues 0.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Capvaxive;
0001628280-25-021834 20240331 Revenues 149000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Rotateq;
0001628280-25-021834 20240331 Revenues 0.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Winrevair;
0001628280-25-021834 20240331 Revenues 440000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Bridion;
0001628280-25-021834 20240331 Revenues 251000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Janumet;
0001628280-25-021834 20240331 Revenues 419000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Januvia;
0001628280-25-021834 20240331 Revenues 632000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Other Pharmaceutical;
0001628280-25-021834 20240331 Revenues 184000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Simponi;
0001628280-25-021834 20240331 Revenues 15517000000.0000 USD 1 us-gaap/2024 Consolidation Items= Operating Segments;
0001628280-25-021834 20240331 Revenues 3563000000.0000 USD 1 us-gaap/2024 Geographical= E M E A;
0001628280-25-021834 20240331 Revenues 796000000.0000 USD 1 us-gaap/2024 Geographical= Latin America;
0001628280-25-021834 20240331 Revenues 8297000000.0000 USD 1 us-gaap/2024 Geographical= Non Us;
0001628280-25-021834 20250331 Revenues 356000000.0000 USD 1 us-gaap/2024 Business Segments= Animal Healthsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Companion Animal;
0001628280-25-021834 20250331 Revenues 64000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Rotateq;
0001628280-25-021834 20250331 Revenues 92000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Vaxneuvance;
0001628280-25-021834 20250331 Revenues 13000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Belsomra;
0001628280-25-021834 20250331 Revenues 106000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Capvaxive;
0001628280-25-021834 20250331 Revenues 4308000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Keytruda;
0001628280-25-021834 20250331 Revenues 106000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Alliance Revenue Adempas Verquvo;
0001628280-25-021834 20250331 Revenues 1327000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Gardasil Gardasil9;
0001628280-25-021834 20250331 Revenues 549000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Januvia;
0001628280-25-021834 20250331 Revenues 93000000.0000 USD 1 us-gaap/2024 Consolidation Items= Corporate Non Segment; Geographical= U S;
0001628280-25-021834 20250331 Revenues 8429000000.0000 USD 1 us-gaap/2024 Consolidation Items= Operating Segments; Geographical= U S;
0001628280-25-021834 20250331 Revenues 9000000.0000 USD 1 us-gaap/2024 Counterparty Name= Bayer A G; Product Or Service= Verquvo; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20250331 Revenues 702000000.0000 USD 1 us-gaap/2024 Geographical= C N;
0001628280-25-021834 20250331 Revenues 701000000.0000 USD 1 us-gaap/2024 Geographical= Other Countries;
0001628280-25-021834 20250331 Selling General And Administrative Expense 9000000.0000 USD 1 us-gaap/2024 Counterparty Name= Daiichi Sankyo; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20250331 Share Based Compensation 195000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20231231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 53895000000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001628280-25-021834 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -5274000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001628280-25-021834 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 56697000000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001628280-25-021834 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -59401000000.0000 USD 0 us-gaap/2024 Equity Components= Treasury Stock Common;
0001628280-25-021834 20250331 Cash And Cash Equivalents At Carrying Value 8629000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20231231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 6909000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20250331 Common Stock Par Or Stated Value Per Share 0.5000 USD 0 us-gaap/2024
0001628280-25-021834 20250331 Comprehensive Income Net Of Tax 5059000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20240331 Cost Of Goods And Services Sold 60000000.0000 USD 1 us-gaap/2024 Counterparty Name= Eisai; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20250331 Cost Of Goods And Services Sold 83000000.0000 USD 1 us-gaap/2024 Counterparty Name= Astra Zeneca; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20250331 Cost Of Goods And Services Sold 58000000.0000 USD 1 us-gaap/2024 Counterparty Name= Bayer A G; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20240331 Deferred Income Tax Expense Benefit -51000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20240331 Depreciation 58000000.0000 USD 1 us-gaap/2024 Business Segments= Animal Healthsegment; Consolidation Items= Operating Segments;
0001628280-25-021834 20240331 Depreciation 452000000.0000 USD 1 us-gaap/2024 Consolidation Items= Corporate Non Segment;
0001628280-25-021834 20250331 Earnings Per Share Basic 2.0100 USD 1 us-gaap/2024
0001628280-25-021834 20240331 Earnings Per Share Diluted 1.8700 USD 1 us-gaap/2024
0001628280-25-021834 20240331 Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents -138000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20240331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest 10904000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments;
0001628280-25-021834 20240331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest 146000000.0000 USD 1 us-gaap/2024 Consolidation Items= Corporate Non Segment;
0001628280-25-021834 20250331 Long Term Debt Noncurrent 33484000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20250331 Marketable Securities Noncurrent 616000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20250331 Net Income Loss Attributable To Noncontrolling Interest 6000000.0000 USD 1 us-gaap/2024 Equity Components= Noncontrolling Interest;
0001628280-25-021834 20241231 Other Assets Noncurrent 546000000.0000 USD 0 us-gaap/2024 Fair Value By Measurement Frequency= Fair Value Measurements Recurring;
0001628280-25-021834 20250331 Other Assets Noncurrent 16768000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20250331 Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent 18000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20240331 Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent -238000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20241231 Other Liabilities Current 57000000.0000 USD 0 us-gaap/2024 Counterparty Name= Moderna Inc.; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20240331 Payments For Proceeds From Other Investing Activities 14000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20250331 Payments Of Dividends Common Stock 2050000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20240331 Payments To Acquire Property Plant And Equipment 861000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20240331 Proceeds From Sale And Maturity Of Other Investments 260000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20241231 Property Plant And Equipment Net 143000000.0000 USD 0 us-gaap/2024 Geographical= J P;
0001628280-25-021834 20240331 Repayments Of Long Term Debt 751000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20231231 Research And Development Expense 5500000000.0000 USD 4 us-gaap/2024 Counterparty Name= Daiichi Sankyo; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20250331 Research And Development Expense 128000000.0000 USD 1 us-gaap/2024 Counterparty Name= Daiichi Sankyo; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20240331 Restructuring Charges 123000000.0000 USD 1 us-gaap/2024 Consolidation Items= Corporate Non Segment;
0001628280-25-021834 20241231 Retained Earnings Accumulated Deficit 63069000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20240331 Revenues 474000000.0000 USD 1 us-gaap/2024 Business Segments= Animal Healthsegment; Consolidation Items= Operating Segments; Geographical= U S;
0001628280-25-021834 20240331 Revenues 70000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Adempas;
0001628280-25-021834 20240331 Revenues 157000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Alliancerevenue Lynparza;
0001628280-25-021834 20240331 Revenues 0.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Capvaxive;
0001628280-25-021834 20240331 Revenues 44000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Delstrigo;
0001628280-25-021834 20240331 Revenues 39000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Remicade;
0001628280-25-021834 20240331 Revenues 0.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Adempas;
0001628280-25-021834 20240331 Revenues 68000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Dificid;
0001628280-25-021834 20240331 Revenues 173000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Lenvima;
0001628280-25-021834 20240331 Revenues 165000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Other Pharmaceutical;
0001628280-25-021834 20240331 Revenues 161000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Vaxneuvance;
0001628280-25-021834 20240331 Revenues 70000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Adempas;
0001628280-25-021834 20240331 Revenues 56000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Delstrigo;
0001628280-25-021834 20250331 Revenues 1086000000.0000 USD 1 us-gaap/2024 Business Segments= Animal Healthsegment; Consolidation Items= Operating Segments; Geographical= Non Us;
0001628280-25-021834 20250331 Revenues 39000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Isentress Isentress H D;
0001628280-25-021834 20250331 Revenues 42000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Pneumovax23;
0001628280-25-021834 20250331 Revenues 28000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Zerbaxa;
0001628280-25-021834 20250331 Revenues 0.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Adempas;
0001628280-25-021834 20250331 Revenues 186000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Lenvima;
0001628280-25-021834 20250331 Revenues 164000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Rotateq;
0001628280-25-021834 20250331 Revenues 268000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Winrevair;
0001628280-25-021834 20250331 Revenues 67000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Delstrigo;
0001628280-25-021834 20250331 Revenues 247000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Janumet;
0001628280-25-021834 20250331 Revenues 137000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Welireg;
0001628280-25-021834 20240331 Selling General And Administrative Expense 3000000.0000 USD 1 us-gaap/2024 Counterparty Name= Daiichi Sankyo; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 106000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Gain Loss Net Cash Flow Hedge Parent;
0001628280-25-021834 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -57445000000.0000 USD 0 us-gaap/2024 Equity Components= Treasury Stock Common;
0001628280-25-021834 20241231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 44704000000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001628280-25-021834 20241231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 59000000.0000 USD 0 us-gaap/2024 Equity Components= Noncontrolling Interest;
0001628280-25-021834 20241231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 63069000000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001628280-25-021834 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 1788000000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001628280-25-021834 20250331 Treasury Stock Common Shares 1061000000.0000 shares 0 us-gaap/2024 Equity Components= Treasury Stock Common;
0001628280-25-021834 20241231 Cash And Cash Equivalents At Carrying Value 13242000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20241231 Accumulated Depreciation Depletion And Amortization Property Plant And Equipment 19155000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20250331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect -4586000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20250331 Common Stock Shares Issued 3577000000.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0001628280-25-021834 20240331 Comprehensive Income Net Of Tax 4649000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20240331 Cost Of Goods And Services Sold 1706000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments;
0001628280-25-021834 20240331 Cost Of Goods And Services Sold 62000000.0000 USD 1 us-gaap/2024 Counterparty Name= Bayer A G; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20250331 Costs Expenses And Other 9626000000.0000 USD 1 0001628280-25-021834
0001628280-25-021834 20241231 Debt Current 2649000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20250331 Deferred Income Tax Liabilities Net 1409000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20240331 Depreciation 511000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20250331 Depreciation 441000000.0000 USD 1 us-gaap/2024 Consolidation Items= Corporate Non Segment;
0001628280-25-021834 20241231 Dividends Payable Current 2084000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20240331 Equity Securities Fv Ni Gain Loss -2000000.0000 USD 1 us-gaap/2024 Financial Instrument= Equity Funds;
0001628280-25-021834 20250331 Equity Securities Fv Ni Gain Loss 90000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20241231 Marketable Securities Current 447000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20241231 Marketable Securities Noncurrent 463000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20240331 Net Cash Provided By Used In Financing Activities -2814000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20250331 Net Cash Provided By Used In Financing Activities -5755000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20240331 Net Income Loss 4762000000.0000 USD 1 us-gaap/2024 Equity Components= Retained Earnings;
0001628280-25-021834 20250331 Other Assets Current 13000000.0000 USD 0 us-gaap/2024 Counterparty Name= Daiichi Sankyo; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20241231 Other Assets Noncurrent 16044000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20241231 Other Assets Noncurrent 546000000.0000 USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level1; Fair Value By Measurement Frequency= Fair Value Measurements Recurring;
0001628280-25-021834 20250331 Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent 215000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20241231 Other Liabilities Current 68000000.0000 USD 0 us-gaap/2024 Counterparty Name= Ridgeback Biotherapeutics L P; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20250331 Other Liabilities Current 83000000.0000 USD 0 us-gaap/2024 Counterparty Name= Bayer A G; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20241231 Property Plant And Equipment Net 982000000.0000 USD 0 us-gaap/2024 Geographical= Asia Pacific;
0001628280-25-021834 20241231 Property Plant And Equipment Net 7548000000.0000 USD 0 us-gaap/2024 Geographical= E M E A;
0001628280-25-021834 20250331 Property Plant And Equipment Net 49000000.0000 USD 0 us-gaap/2024 Geographical= Other Countries;
0001628280-25-021834 20250331 Research And Development Expense 3621000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20240331 Revenues 308000000.0000 USD 1 us-gaap/2024 Business Segments= Animal Healthsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Companion Animal;
0001628280-25-021834 20240331 Revenues 7070000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us;
0001628280-25-021834 20240331 Revenues 8000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Alliance Revenue Adempas Verquvo;
0001628280-25-021834 20240331 Revenues 82000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Lenvima;
0001628280-25-021834 20240331 Revenues 7000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Welireg;
0001628280-25-021834 20240331 Revenues 90000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Alliance Revenue Adempas Verquvo;
0001628280-25-021834 20240331 Revenues 135000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Alliancerevenue Lynparza;
0001628280-25-021834 20240331 Revenues 50000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Isentress Isentress H D;
0001628280-25-021834 20240331 Revenues 45000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Lagevrio;
0001628280-25-021834 20240331 Revenues 29000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Pifeltro;
0001628280-25-021834 20240331 Revenues 74000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Prevymis;
0001628280-25-021834 20240331 Revenues 46000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Belsomra;
0001628280-25-021834 20240331 Revenues 73000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Dificid;
0001628280-25-021834 20240331 Revenues 219000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Vaxneuvance;
0001628280-25-021834 20240331 Revenues 258000000.0000 USD 1 us-gaap/2024 Consolidation Items= Corporate Non Segment;
0001628280-25-021834 20240331 Revenues 173000000.0000 USD 1 us-gaap/2024 Counterparty Name= Bayer A G; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20240331 Revenues 7478000000.0000 USD 1 us-gaap/2024 Geographical= U S;
0001628280-25-021834 20250331 Revenues 924000000.0000 USD 1 us-gaap/2024 Business Segments= Animal Healthsegment; Consolidation Items= Operating Segments; Product Or Service= Livestock;
0001628280-25-021834 20250331 Revenues 5711000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us;
0001628280-25-021834 20250331 Revenues 168000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Alliancerevenue Lynparza;
0001628280-25-021834 20250331 Revenues 1000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Capvaxive;
0001628280-25-021834 20250331 Revenues 204000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Januvia;
0001628280-25-021834 20250331 Revenues 97000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Alliance Revenue Adempas Verquvo;
0001628280-25-021834 20250331 Revenues 15000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Delstrigo;
0001628280-25-021834 20250331 Revenues 102000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Prevymis;
0001628280-25-021834 20250331 Revenues 423000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Pro Quad M M R I I Varivax;
0001628280-25-021834 20250331 Revenues 0.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Remicade;
0001628280-25-021834 20250331 Revenues 102000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Lagevrio;
0001628280-25-021834 20250331 Revenues 45000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Pifeltro;
0001628280-25-021834 20250331 Revenues 0.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Simponi;
0001628280-25-021834 20250331 Revenues 210000000.0000 USD 1 us-gaap/2024 Consolidation Items= Corporate Non Segment; Geographical= Non Us;
0001628280-25-021834 20250331 Revenues 74000000.0000 USD 1 us-gaap/2024 Derivative Instrument Risk= Foreign Exchange Contract; Equity Components= Accumulated Gain Loss Cash Flow Hedge Including Noncontrolling Interest; Reclassification Out Of Accumulated Other Comprehensive Income= Reclassification Out Of Accumulated Other Comprehensive Income;
0001628280-25-021834 20250331 Revenues 689000000.0000 USD 1 us-gaap/2024 Geographical= Asia Pacific;
0001628280-25-021834 20250331 Revenues 669000000.0000 USD 1 us-gaap/2024 Geographical= J P;
0001628280-25-021834 20250331 Revenues 8522000000.0000 USD 1 us-gaap/2024 Geographical= U S;
0001628280-25-021834 20240331 Selling General And Administrative Expense 33000000.0000 USD 1 us-gaap/2024 Counterparty Name= Bayer A G; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20250331 Selling General And Administrative Expense 29000000.0000 USD 1 us-gaap/2024 Counterparty Name= Bayer A G; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20241231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 1788000000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001628280-25-021834 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 48400000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -2345000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Defined Benefit Plans Adjustment;
0001628280-25-021834 20240331 Treasury Stock Common Shares 1044000000.0000 shares 0 us-gaap/2024 Equity Components= Treasury Stock Common;
0001628280-25-021834 20240331 Adjustment For Amortization 473000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20250331 Allowance For Doubtful Accounts Receivable Current 93000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20250331 Assets Current 160000000.0000 USD 0 us-gaap/2024 Counterparty Name= Bayer A G; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20240331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 5671000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20241231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 13318000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20241231 Common Stock Par Or Stated Value Per Share 0.5000 USD 0 us-gaap/2024
0001628280-25-021834 20231231 Common Stock Shares Issued 3577000000.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0001628280-25-021834 20250331 Common Stock Shares Issued 3577103522.0000 shares 0 us-gaap/2024
0001628280-25-021834 20250331 Common Stock Value 1788000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20240331 Costs Expenses And Other 10105000000.0000 USD 1 0001628280-25-021834
0001628280-25-021834 20241231 Deferred Income Tax Liabilities Net 1387000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20240331 Depreciation 1000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments;
0001628280-25-021834 20250331 Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 156000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20241231 Goodwill 21668000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20250331 Goodwill 21684000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20240331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest 11459000000.0000 USD 1 us-gaap/2024 Consolidation Items= Operating Segments;
0001628280-25-021834 20250331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest 634000000.0000 USD 1 us-gaap/2024 Business Segments= Animal Healthsegment; Consolidation Items= Operating Segments;
0001628280-25-021834 20250331 Income Tax Expense Benefit 818000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20250331 Intangible Assets Net Excluding Goodwill 15758000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20241231 Inventory Net 6109000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20241231 Inventory Noncurrent 4193000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20250331 Inventory Noncurrent 544000000.0000 USD 0 us-gaap/2024 Public Utilities Inventory= Inventories Producedin Preparationfor Product Launches;
0001628280-25-021834 20250331 Marketable Securities Current 599000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20250331 Minority Interest 65000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20240331 Net Cash Provided By Used In Investing Activities -1376000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20250331 Other Assets Noncurrent 0.0000 USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level3; Fair Value By Measurement Frequency= Fair Value Measurements Recurring;
0001628280-25-021834 20250331 Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent -217000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20240331 Other Nonoperating Income Expense 1000000.0000 USD 1 us-gaap/2024 Business Segments= Animal Healthsegment; Consolidation Items= Operating Segments;
0001628280-25-021834 20250331 Proceeds From Stock Options Exercised 19000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20241231 Property Plant And Equipment Net 23779000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20250331 Property Plant And Equipment Net 8402000000.0000 USD 0 us-gaap/2024 Geographical= E M E A;
0001628280-25-021834 20250331 Property Plant And Equipment Net 145000000.0000 USD 0 us-gaap/2024 Geographical= J P;
0001628280-25-021834 20250331 Repayments Of Long Term Debt 2500000000.0000 USD 1 us-gaap/2024
0001628280-25-021834 20240331 Research And Development Expense 20000000.0000 USD 1 us-gaap/2024 Counterparty Name= Astra Zeneca; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20250331 Research And Development Expense 95000000.0000 USD 1 us-gaap/2024 Business Segments= Animal Healthsegment; Consolidation Items= Operating Segments;
0001628280-25-021834 20240331 Restricted Cash And Cash Equivalents 92000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20240331 Revenues 32000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Belsomra;
0001628280-25-021834 20240331 Revenues 1761000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Gardasil Gardasil9;
0001628280-25-021834 20240331 Revenues 236000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Januvia;
0001628280-25-021834 20240331 Revenues 13000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Pifeltro;
0001628280-25-021834 20240331 Revenues 133000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Pro Quad M M R I I Varivax;
0001628280-25-021834 20240331 Revenues 67000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Rotateq;
0001628280-25-021834 20240331 Revenues 23000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Zerbaxa;
0001628280-25-021834 20240331 Revenues 15000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Belsomra;
0001628280-25-021834 20240331 Revenues 183000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Januvia;
0001628280-25-021834 20240331 Revenues 4119000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Keytruda;
0001628280-25-021834 20240331 Revenues 6000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Pneumovax23;
0001628280-25-021834 20240331 Revenues 0.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Winrevair;
0001628280-25-021834 20240331 Revenues 56000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Zerbaxa;
0001628280-25-021834 20240331 Revenues 8107000000.0000 USD 1 us-gaap/2024 Consolidation Items= Operating Segments; Geographical= Non Us;
0001628280-25-021834 20250331 Revenues 1588000000.0000 USD 1 us-gaap/2024 Business Segments= Animal Healthsegment; Consolidation Items= Operating Segments;
0001628280-25-021834 20250331 Revenues 502000000.0000 USD 1 us-gaap/2024 Business Segments= Animal Healthsegment; Consolidation Items= Operating Segments; Geographical= U S;
0001628280-25-021834 20250331 Revenues 664000000.0000 USD 1 us-gaap/2024 Business Segments= Animal Healthsegment; Consolidation Items= Operating Segments; Product Or Service= Companion Animal;
0001628280-25-021834 20250331 Revenues 18000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Alliance Revenue Reblozyl;
0001628280-25-021834 20250331 Revenues 37000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Belsomra;
0001628280-25-021834 20250331 Revenues 116000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Pro Quad M M R I I Varivax;
0001628280-25-021834 20250331 Revenues 0.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Simponi;
0001628280-25-021834 20250331 Revenues 15000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= Non Us; Product Or Service= Welireg;
0001628280-25-021834 20250331 Revenues 72000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Dificid;
0001628280-25-021834 20250331 Revenues -2000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Pneumovax23;
0001628280-25-021834 20250331 Revenues 0.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Geographical= U S; Product Or Service= Simponi;
0001628280-25-021834 20250331 Revenues 7205000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Keytruda;
0001628280-25-021834 20250331 Revenues 258000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Lenvima;
0001628280-25-021834 20250331 Revenues 0.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments; Product Or Service= Remicade;
0001628280-25-021834 20250331 Revenues 68000000.0000 USD 1 us-gaap/2024 Counterparty Name= Bayer A G; Product Or Service= Adempas; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20250331 Revenues 792000000.0000 USD 1 us-gaap/2024 Geographical= Latin America;
0001628280-25-021834 20250331 Revenues 7007000000.0000 USD 1 us-gaap/2024 Geographical= Non Us;
0001628280-25-021834 20240331 Selling General And Administrative Expense 252000000.0000 USD 1 us-gaap/2024 Business Segments= Animal Healthsegment; Consolidation Items= Operating Segments;
0001628280-25-021834 20240331 Selling General And Administrative Expense 39000000.0000 USD 1 us-gaap/2024 Counterparty Name= Eisai; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20240331 Selling General And Administrative Expense 16000000.0000 USD 1 us-gaap/2024 Counterparty Name= Ridgeback Biotherapeutics L P; Type Of Arrangement= Collaborative Arrangement Transaction With Party To Collaborative Arrangement;
0001628280-25-021834 20250331 Selling General And Administrative Expense 260000000.0000 USD 1 us-gaap/2024 Business Segments= Animal Healthsegment; Consolidation Items= Operating Segments;
0001628280-25-021834 20250331 Selling General And Administrative Expense 1402000000.0000 USD 1 us-gaap/2024 Business Segments= Pharmaceuticalsegment; Consolidation Items= Operating Segments;
0001628280-25-021834 20231231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -2793000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Defined Benefit Plans Adjustment;
0001628280-25-021834 20231231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 44509000000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001628280-25-021834 20241231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 46372000000.0000 USD 0 us-gaap/2024
0001628280-25-021834 20241231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -2860000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Translation Adjustment;
0001628280-25-021834 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 66097000000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001628280-25-021834 20250331 Treasury Stock Common Value 59401000000.0000 USD 0 us-gaap/2024

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
tag The unique identifier (name) for a tag in a specific taxonomy release.
version For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined.
ddate The end date for the data value, rounded to the nearest month end.
qtrs The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value.
uom The unit of measure for the value.
segments Tags used to represent axis and member reporting.
coreg If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity.
value The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point.
footnote The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank.

Tags

tag version custom abstract datatype iord crdr tlabel doc
Assets Current us-gaap/2024 0 0 monetary I D Assets, Current Amount of asset recognized for present right to economic benefit, classified as current.
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 0 0 monetary I D Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Payments To Acquire Businesses Net Of Cash Acquired us-gaap/2024 0 0 monetary D C Payments to Acquire Businesses, Net of Cash Acquired The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.
Payments To Acquire Property Plant And Equipment us-gaap/2024 0 0 monetary D C Payments to Acquire Property, Plant, and Equipment The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
Stockholders Equity Including Portion Attributable To Noncontrolling Interest us-gaap/2024 0 0 monetary I C Equity, Including Portion Attributable to Noncontrolling Interest Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment us-gaap/2024 0 0 monetary I C Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
Allowance For Doubtful Accounts Receivable Current us-gaap/2024 0 0 monetary I C Accounts Receivable, Allowance for Credit Loss, Current Amount of allowance for credit loss on accounts receivable, classified as current.
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest us-gaap/2024 0 0 monetary D C Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Comprehensive Income Net Of Tax us-gaap/2024 0 0 monetary D C Comprehensive Income (Loss), Net of Tax, Attributable to Parent Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
Increase Decrease In Operating Capital us-gaap/2024 0 0 monetary D C Increase (Decrease) in Operating Capital The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.
Net Income Loss Attributable To Noncontrolling Interest us-gaap/2024 0 0 monetary D D Net Income (Loss) Attributable to Noncontrolling Interest Amount of Net Income (Loss) attributable to noncontrolling interest.
Liabilities And Stockholders Equity us-gaap/2024 0 0 monetary I C Liabilities and Equity Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
Proceeds From Stock Options Exercised us-gaap/2024 0 0 monetary D D Proceeds from Stock Options Exercised Amount of cash inflow from exercise of option under share-based payment arrangement.
Accounts Receivable Net Current us-gaap/2024 0 0 monetary I D Accounts Receivable, after Allowance for Credit Loss, Current Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Retained Earnings Accumulated Deficit us-gaap/2024 0 0 monetary I C Retained Earnings (Accumulated Deficit) Amount of accumulated undistributed earnings (deficit).
Common Stock Par Or Stated Value Per Share us-gaap/2024 0 0 perShare I Common Stock, Par or Stated Value Per Share Face amount or stated value per share of common stock.
Debt Current us-gaap/2024 0 0 monetary I C Debt, Current Amount of debt and lease obligation, classified as current.
Net Income Loss us-gaap/2024 0 0 monetary D C Net Income (Loss) Attributable to Parent The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Income Tax Expense Benefit us-gaap/2024 0 0 monetary D D Income Tax Expense (Benefit) Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Payments To Acquire Investments us-gaap/2024 0 0 monetary D C Payments to Acquire Investments The cash outflow associated with the purchase of all investments (debt, security, other) during the period.
Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent us-gaap/2024 0 0 monetary D D Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.
Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent us-gaap/2024 0 0 monetary D C Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.
Costs Expenses And Other 0001628280-25-021834 1 0 monetary D D Costs Expenses And Other Total of cost of sales, operating expenses and nonoperating income or expense.
Stockholders Equity us-gaap/2024 0 0 monetary I C Equity, Attributable to Parent Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
Accumulated Other Comprehensive Income Loss Net Of Tax us-gaap/2024 0 0 monetary I C Accumulated Other Comprehensive Income (Loss), Net of Tax Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.
Assets us-gaap/2024 0 0 monetary I D Assets Amount of asset recognized for present right to economic benefit.
Common Stock Shares Issued us-gaap/2024 0 0 shares I Common Stock, Shares, Issued Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
Cost Of Goods And Services Sold us-gaap/2024 0 0 monetary D D Cost of Goods and Services Sold The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
Earnings Per Share Diluted us-gaap/2024 0 0 perShare D Earnings Per Share, Diluted The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 0 0 monetary D D Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Other Assets Noncurrent us-gaap/2024 0 0 monetary I D Other Assets, Noncurrent Amount of noncurrent assets classified as other.
Payments For Proceeds From Other Investing Activities us-gaap/2024 0 0 monetary D C Payments for (Proceeds from) Other Investing Activities Amount of cash (inflow) outflow from investing activities classified as other.
Research And Development Asset Acquired Other Than Through Business Combination Written Off us-gaap/2024 0 0 monetary D D Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Writeoff Amount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both.
Marketable Securities Current us-gaap/2024 0 0 monetary I D Marketable Securities, Current Amount of investment in marketable security, classified as current.
Selling General And Administrative Expense us-gaap/2024 0 0 monetary D D Selling, General and Administrative Expense The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
Liabilities Current us-gaap/2024 0 0 monetary I C Liabilities, Current Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
Repayments Of Long Term Debt us-gaap/2024 0 0 monetary D C Repayments of Long-Term Debt The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.
Restructuring Charges us-gaap/2024 0 0 monetary D D Restructuring Charges Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.
Share Based Compensation us-gaap/2024 0 0 monetary D D Share-Based Payment Arrangement, Noncash Expense Amount of noncash expense for share-based payment arrangement.
Common Stock Value us-gaap/2024 0 0 monetary I C Common Stock, Value, Issued Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
Cash And Cash Equivalents At Carrying Value us-gaap/2024 0 0 monetary I D Cash and Cash Equivalents, at Carrying Value Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
Dividends Payable Current us-gaap/2024 0 0 monetary I C Dividends Payable, Current Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Other Liabilities Current us-gaap/2024 0 0 monetary I C Other Liabilities, Current Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.
Other Noncash Income Expense us-gaap/2024 0 0 monetary D C Other Noncash Income (Expense) Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.
Profit Loss us-gaap/2024 0 0 monetary D C Net Income (Loss), Including Portion Attributable to Noncontrolling Interest The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
Accrued Income Taxes Current us-gaap/2024 0 0 monetary I C Accrued Income Taxes, Current Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.
Deferred Income Tax Expense Benefit us-gaap/2024 0 0 monetary D D Deferred Income Tax Expense (Benefit) Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Goodwill us-gaap/2024 0 0 monetary I D Goodwill Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.
Intangible Assets Net Excluding Goodwill us-gaap/2024 0 0 monetary I D Intangible Assets, Net (Excluding Goodwill) Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
Net Cash Provided By Used In Operating Activities us-gaap/2024 0 0 monetary D Net Cash Provided by (Used in) Operating Activities Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
Other Assets Current us-gaap/2024 0 0 monetary I D Other Assets, Current Amount of current assets classified as other.
Other Liabilities Noncurrent us-gaap/2024 0 0 monetary I C Other Liabilities, Noncurrent Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
Proceeds From Payments For Other Financing Activities us-gaap/2024 0 0 monetary D D Proceeds from (Payments for) Other Financing Activities Amount of cash inflow (outflow) from financing activities classified as other.
Stockholders Equity Before Treasury Stock us-gaap/2024 0 0 monetary I C Stockholders' Equity before Treasury Stock Total amount of stockholders' equity (deficit) items including stock value, paid in capital, retained earnings and including equity attributable to noncontrolling interests and before deducting the carrying value of treasury stock.
Inventory Net us-gaap/2024 0 0 monetary I D Inventory, Net Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
Inventory Noncurrent us-gaap/2024 0 0 monetary I D Inventory, Noncurrent Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.
Marketable Securities Noncurrent us-gaap/2024 0 0 monetary I D Marketable Securities, Noncurrent Amount of investment in marketable security, classified as noncurrent.
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent us-gaap/2024 0 0 monetary D C Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Amount after tax of other comprehensive income (loss) attributable to parent entity.
Research And Development Expense us-gaap/2024 0 0 monetary D D Research and Development Expense Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.
Revenues us-gaap/2024 0 0 monetary D C Revenues Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
Accounts Payable Current us-gaap/2024 0 0 monetary I C Accounts Payable, Current Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Additional Paid In Capital Common Stock us-gaap/2024 0 0 monetary I C Additional Paid in Capital, Common Stock Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect us-gaap/2024 0 0 monetary D D Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Common Stock Shares Authorized us-gaap/2024 0 0 shares I Common Stock, Shares Authorized The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
Deferred Income Tax Liabilities Net us-gaap/2024 0 0 monetary I C Deferred Income Tax Liabilities, Net Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.
Equity Securities Fv Ni Gain Loss us-gaap/2024 0 0 monetary D C Equity Securities, FV-NI, Gain (Loss) Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).
Net Cash Provided By Used In Financing Activities us-gaap/2024 0 0 monetary D D Net Cash Provided by (Used in) Financing Activities Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent us-gaap/2024 0 0 monetary D C Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.
Payments For Repurchase Of Common Stock us-gaap/2024 0 0 monetary D C Payments for Repurchase of Common Stock The cash outflow to reacquire common stock during the period.
Proceeds From Sale And Maturity Of Other Investments us-gaap/2024 0 0 monetary D D Proceeds from Sale and Maturity of Other Investments The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.
Depreciation us-gaap/2024 0 0 monetary D D Depreciation The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Earnings Per Share Basic us-gaap/2024 0 0 perShare D Earnings Per Share, Basic The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
Net Cash Provided By Used In Investing Activities us-gaap/2024 0 0 monetary D D Net Cash Provided by (Used in) Investing Activities Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
Other Nonoperating Income Expense us-gaap/2024 0 0 monetary D C Other Nonoperating Income (Expense) Amount of income (expense) related to nonoperating activities, classified as other.
Restricted Cash And Cash Equivalents us-gaap/2024 0 0 monetary I D Restricted Cash and Cash Equivalents Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Treasury Stock Common Value us-gaap/2024 0 0 monetary I D Treasury Stock, Common, Value Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.
Adjustment For Amortization us-gaap/2024 0 0 monetary D D Amortization The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.
Long Term Debt Noncurrent us-gaap/2024 0 0 monetary I C Long-Term Debt, Excluding Current Maturities Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.
Minority Interest us-gaap/2024 0 0 monetary I C Equity, Attributable to Noncontrolling Interest Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.
Payments Of Dividends Common Stock us-gaap/2024 0 0 monetary D C Payments of Ordinary Dividends, Common Stock Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.
Property Plant And Equipment Net us-gaap/2024 0 0 monetary I D Property, Plant and Equipment, Net Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
Treasury Stock Common Shares us-gaap/2024 0 0 shares I Treasury Stock, Common, Shares Number of previously issued common shares repurchased by the issuing entity and held in treasury.

Description
Field Name Field Description
tag The unique identifier (name) for a tag in a specific taxonomy release.
version For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined.
custom 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns.
abstract 1 if the tag is not used to represent a numeric fact.
datatype If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag.
iord If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration.
crdr If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL.
tlabel If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here.
doc The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL.

Presentation of Statements

adsh report line stmt inpth rfile tag version plabel negating
0001628280-25-021834 2 1 IS 0 H Revenues us-gaap/2024 Sales 0
0001628280-25-021834 2 3 IS 0 H Cost Of Goods And Services Sold us-gaap/2024 Cost of sales 0
0001628280-25-021834 2 4 IS 0 H Selling General And Administrative Expense us-gaap/2024 Selling, general and administrative 0
0001628280-25-021834 2 5 IS 0 H Research And Development Expense us-gaap/2024 Research and development 0
0001628280-25-021834 2 6 IS 0 H Restructuring Charges us-gaap/2024 Restructuring costs 0
0001628280-25-021834 2 7 IS 0 H Other Nonoperating Income Expense us-gaap/2024 Other (income) expense, net 1
0001628280-25-021834 2 8 IS 0 H Costs Expenses And Other 0001628280-25-021834 Total Costs, Expenses and Other 0
0001628280-25-021834 2 9 IS 0 H Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest us-gaap/2024 Income Before Taxes 0
0001628280-25-021834 2 10 IS 0 H Income Tax Expense Benefit us-gaap/2024 Taxes on Income 0
0001628280-25-021834 2 11 IS 0 H Profit Loss us-gaap/2024 Net Income 0
0001628280-25-021834 2 12 IS 0 H Net Income Loss Attributable To Noncontrolling Interest us-gaap/2024 Less: Net Income Attributable to Noncontrolling Interests 0
0001628280-25-021834 2 13 IS 0 H Net Income Loss us-gaap/2024 Net Income Attributable to Merck & Co., Inc. 0
0001628280-25-021834 2 14 IS 0 H Earnings Per Share Basic us-gaap/2024 Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) 0
0001628280-25-021834 2 15 IS 0 H Earnings Per Share Diluted us-gaap/2024 Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) 0
0001628280-25-021834 3 1 CI 0 H Net Income Loss us-gaap/2024 Net Income Attributable to Merck & Co., Inc. 0
0001628280-25-021834 3 3 CI 0 H Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent us-gaap/2024 Net unrealized (loss) gain on derivatives, net of reclassifications 0
0001628280-25-021834 3 4 CI 0 H Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent us-gaap/2024 Benefit plan net (loss) gain and prior service (cost) credit, net of amortization 1
0001628280-25-021834 3 5 CI 0 H Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent us-gaap/2024 Cumulative translation adjustment 0
0001628280-25-021834 3 6 CI 0 H Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent us-gaap/2024 Other comprehensive income (loss), net of taxes 0
0001628280-25-021834 3 7 CI 0 H Comprehensive Income Net Of Tax us-gaap/2024 Comprehensive Income Attributable to Merck & Co., Inc. 0
0001628280-25-021834 4 3 BS 0 H Cash And Cash Equivalents At Carrying Value us-gaap/2024 Cash and cash equivalents 0
0001628280-25-021834 4 4 BS 0 H Marketable Securities Current us-gaap/2024 Short-term investments 0
0001628280-25-021834 4 5 BS 0 H Accounts Receivable Net Current us-gaap/2024 Accounts receivable (net of allowance for doubtful accounts of $93 in 2025 and $89 in 2024) 0
0001628280-25-021834 4 6 BS 0 H Inventory Net us-gaap/2024 Inventories (excludes inventories of $4,556 in 2025 and $4,193 in 2024 classified in Other assets - see Note 6) 0
0001628280-25-021834 4 7 BS 0 H Other Assets Current us-gaap/2024 Other current assets 0
0001628280-25-021834 4 8 BS 0 H Assets Current us-gaap/2024 Total current assets 0
0001628280-25-021834 4 9 BS 0 H Marketable Securities Noncurrent us-gaap/2024 Investments 0
0001628280-25-021834 4 10 BS 0 H Property Plant And Equipment Net us-gaap/2024 Property, Plant and Equipment, at cost, net of accumulated depreciation of $19,680 in 2025 and $19,155 in 2024 0
0001628280-25-021834 4 11 BS 0 H Goodwill us-gaap/2024 Goodwill 0
0001628280-25-021834 4 12 BS 0 H Intangible Assets Net Excluding Goodwill us-gaap/2024 Other Intangibles, Net 0
0001628280-25-021834 4 13 BS 0 H Other Assets Noncurrent us-gaap/2024 Other Assets 0
0001628280-25-021834 4 14 BS 0 H Assets us-gaap/2024 Total Assets 0
0001628280-25-021834 4 17 BS 0 H Debt Current us-gaap/2024 Loans payable and current portion of long-term debt 0
0001628280-25-021834 4 18 BS 0 H Accounts Payable Current us-gaap/2024 Trade accounts payable 0
0001628280-25-021834 4 19 BS 0 H Other Liabilities Current us-gaap/2024 Accrued and other current liabilities 0
0001628280-25-021834 4 20 BS 0 H Accrued Income Taxes Current us-gaap/2024 Income taxes payable 0
0001628280-25-021834 4 21 BS 0 H Dividends Payable Current us-gaap/2024 Dividends payable 0
0001628280-25-021834 4 22 BS 0 H Liabilities Current us-gaap/2024 Total current liabilities 0
0001628280-25-021834 4 23 BS 0 H Long Term Debt Noncurrent us-gaap/2024 Long-Term Debt 0
0001628280-25-021834 4 24 BS 0 H Deferred Income Tax Liabilities Net us-gaap/2024 Deferred Income Taxes 0
0001628280-25-021834 4 25 BS 0 H Other Liabilities Noncurrent us-gaap/2024 Other Noncurrent Liabilities 0
0001628280-25-021834 4 27 BS 0 H Common Stock Value us-gaap/2024 Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2025 and 2024 0
0001628280-25-021834 4 28 BS 0 H Additional Paid In Capital Common Stock us-gaap/2024 Other paid-in capital 0
0001628280-25-021834 4 29 BS 0 H Retained Earnings Accumulated Deficit us-gaap/2024 Retained earnings 0
0001628280-25-021834 4 30 BS 0 H Accumulated Other Comprehensive Income Loss Net Of Tax us-gaap/2024 Accumulated other comprehensive loss 0
0001628280-25-021834 4 31 BS 0 H Stockholders Equity Before Treasury Stock us-gaap/2024 Stockholders' equity before deduction for treasury stock 0
0001628280-25-021834 4 32 BS 0 H Treasury Stock Common Value us-gaap/2024 Less treasury stock, at cost: 1,061,021,894 shares in 2025 and 1,049,466,187 shares in 2024 0
0001628280-25-021834 4 33 BS 0 H Stockholders Equity us-gaap/2024 Total Merck & Co., Inc. stockholders equity 0
0001628280-25-021834 4 34 BS 0 H Minority Interest us-gaap/2024 Noncontrolling Interests 0
0001628280-25-021834 4 35 BS 0 H Stockholders Equity Including Portion Attributable To Noncontrolling Interest us-gaap/2024 Total equity 0
0001628280-25-021834 4 36 BS 0 H Liabilities And Stockholders Equity us-gaap/2024 Liabilities and Equity 0
0001628280-25-021834 5 1 BS 1 H Allowance For Doubtful Accounts Receivable Current us-gaap/2024 Allowance for doubtful accounts 0
0001628280-25-021834 5 2 BS 1 H Inventory Noncurrent us-gaap/2024 Inventories classified in Other assets 0
0001628280-25-021834 5 3 BS 1 H Accumulated Depreciation Depletion And Amortization Property Plant And Equipment us-gaap/2024 Accumulated depreciation 0
0001628280-25-021834 5 4 BS 1 H Common Stock Par Or Stated Value Per Share us-gaap/2024 Common stock, par value (in dollars per share) 0
0001628280-25-021834 5 5 BS 1 H Common Stock Shares Authorized us-gaap/2024 Common stock, authorized (shares) 0
0001628280-25-021834 5 6 BS 1 H Common Stock Shares Issued us-gaap/2024 Common stock, issued (in shares) 0
0001628280-25-021834 5 7 BS 1 H Treasury Stock Common Shares us-gaap/2024 Treasury stock (in shares) 0
0001628280-25-021834 6 2 CF 0 H Profit Loss us-gaap/2024 Net income 0
0001628280-25-021834 6 4 CF 0 H Adjustment For Amortization us-gaap/2024 Amortization 0
0001628280-25-021834 6 5 CF 0 H Depreciation us-gaap/2024 Depreciation 0
0001628280-25-021834 6 6 CF 0 H Equity Securities Fv Ni Gain Loss us-gaap/2024 Income from investments in equity securities, net 1
0001628280-25-021834 6 7 CF 0 H Research And Development Asset Acquired Other Than Through Business Combination Written Off us-gaap/2024 Charge for research and development asset acquisition 0
0001628280-25-021834 6 8 CF 0 H Deferred Income Tax Expense Benefit us-gaap/2024 Deferred income taxes 0
0001628280-25-021834 6 9 CF 0 H Share Based Compensation us-gaap/2024 Share-based compensation 0
0001628280-25-021834 6 10 CF 0 H Other Noncash Income Expense us-gaap/2024 Other 1
0001628280-25-021834 6 11 CF 0 H Increase Decrease In Operating Capital us-gaap/2024 Net changes in assets and liabilities 1
0001628280-25-021834 6 12 CF 0 H Net Cash Provided By Used In Operating Activities us-gaap/2024 Net Cash Provided by Operating Activities 0
0001628280-25-021834 6 14 CF 0 H Payments To Acquire Property Plant And Equipment us-gaap/2024 Capital expenditures 1
0001628280-25-021834 6 15 CF 0 H Payments To Acquire Investments us-gaap/2024 Purchases of securities and other investments 1
0001628280-25-021834 6 16 CF 0 H Proceeds From Sale And Maturity Of Other Investments us-gaap/2024 Proceeds from sales of securities and other investments 0
0001628280-25-021834 6 17 CF 0 H Payments To Acquire Businesses Net Of Cash Acquired us-gaap/2024 Acquisition of Harpoon Therapeutics, Inc., net of cash acquired 1
0001628280-25-021834 6 18 CF 0 H Payments For Proceeds From Other Investing Activities us-gaap/2024 Other 1
0001628280-25-021834 6 19 CF 0 H Net Cash Provided By Used In Investing Activities us-gaap/2024 Net Cash Used in Investing Activities 0
0001628280-25-021834 6 21 CF 0 H Repayments Of Long Term Debt us-gaap/2024 Payments on debt 1
0001628280-25-021834 6 22 CF 0 H Payments Of Dividends Common Stock us-gaap/2024 Dividends paid to stockholders 1
0001628280-25-021834 6 23 CF 0 H Payments For Repurchase Of Common Stock us-gaap/2024 Purchases of treasury stock 1
0001628280-25-021834 6 24 CF 0 H Proceeds From Stock Options Exercised us-gaap/2024 Proceeds from exercise of stock options 0
0001628280-25-021834 6 25 CF 0 H Proceeds From Payments For Other Financing Activities us-gaap/2024 Other 0
0001628280-25-021834 6 26 CF 0 H Net Cash Provided By Used In Financing Activities us-gaap/2024 Net Cash Used in Financing Activities 0
0001628280-25-021834 6 27 CF 0 H Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash 0
0001628280-25-021834 6 28 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect us-gaap/2024 Net Decrease in Cash, Cash Equivalents and Restricted Cash 0
0001628280-25-021834 6 29 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $76 and $68 at January 1, 2025 and 2024, respectively, included in Other current assets) 0
0001628280-25-021834 6 30 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $103 and $92 at March 31, 2025 and 2024, respectively, included in Other current assets) 0
0001628280-25-021834 7 1 CF 1 H Restricted Cash And Cash Equivalents us-gaap/2024 Restricted cash 0

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
report Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site.
line Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived.
stmt The financial statement location to which the value of the “report” field pertains.
inpth Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700.
rfile The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file.
tag The tag chosen by the filer for this line item.
version The taxonomy identifier if the tag is a standard tag, otherwise adsh.
plabel The text presented on the line item, also known as a “preferred” label.
negating Flag to indicate whether the plabel is negating.